Am I reading this wrong?PRICE TARGET SCENARIOS
TARGET SCENARIO ($3.00, +133%)
Thetarget scenario is based on the company obtaining FDA approval ofUrocidin and commercial launch by F2015, in addition to the grant of theU.S. conditional commercial license for the E.coli vaccine by the USDAin C2011. This is supported by a stable Animal Health business over thecoming years. Sum-of-the-parts valuation: Human Health $2.53, FoodSafety
.19 and Animal Health
.37.
The $3.00 target price is what they estimate eventually with the approval and commercialization of Urocidin?
I asked the same question back in Jan and someone told me this is the 12 month TP. But according to this quote "commercial launch by F2015", it does not sound like 12-month to me.
My own opinion is that if Urocidin gets to the market. it will be worth way higher than $3.00.
Anyone wants to clarify this point of confusion?